Joshua P. Plotnik
Indiana University Bloomington
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joshua P. Plotnik.
Molecular and Cellular Biology | 2015
Nagarathinam Selvaraj; Justin A. Budka; Mary W. Ferris; Joshua P. Plotnik; Peter C. Hollenhorst
ABSTRACT JUN transcription factors bind DNA as part of the AP-1 complex, regulate many cellular processes, and play a key role in oncogenesis. The three JUN proteins (c-JUN, JUNB, and JUND) can have both redundant and unique functions depending on the biological phenotype and cell type assayed. Mechanisms that allow this dynamic switching between overlapping and distinct functions are unclear. Here we demonstrate that JUND has a role in prostate cell migration that is the opposite of c-JUN’s and JUNBs. RNA sequencing reveals that opposing regulation by c-JUN and JUND defines a subset of AP-1 target genes with cell migration roles. cis-regulatory elements for only this subset of targets were enriched for ETS factor binding, indicating a specificity mechanism. Interestingly, the function of c-JUN and JUND in prostate cell migration switched when we compared cells with an inactive versus an active RAS/extracellular signal-regulated kinase (ERK) signaling pathway. We show that this switch is due to phosphorylation and activation of JUND by ERK. Thus, the ETS/AP-1 sequence defines a unique gene expression program regulated by the relative levels of JUN proteins and RAS/ERK signaling. This work provides a rationale for how transcription factors can have distinct roles depending on the signaling status and the biological function in question.
Cell Reports | 2016
Vivekananda Kedage; Nagarathinam Selvaraj; Taylor R. Nicholas; Justin A. Budka; Joshua P. Plotnik; Travis J. Jerde; Peter C. Hollenhorst
More than 50% of prostate tumors have a chromosomal rearrangement resulting in aberrant expression of an oncogenic ETS family transcription factor. However, mechanisms that differentiate the function of oncogenic ETS factors expressed in prostate tumors from non-oncogenic ETS factors expressed in normal prostate are unknown. Here, we find that four oncogenic ETS (ERG, ETV1, ETV4, and ETV5), and no other ETS, interact with the Ewings sarcoma breakpoint protein, EWS. This EWS interaction was necessary and sufficient for oncogenic ETS functions including gene activation, cell migration, clonogenic survival, and transformation. Significantly, the EWS interacting region of ERG has no homology with that of ETV1, ETV4, and ETV5. Therefore, this finding may explain how divergent ETS factors have a common oncogenic function. Strikingly, EWS is fused to various ETS factors by the chromosome translocations that cause Ewings sarcoma. Therefore, these findings link oncogenic ETS function in both prostate cancer and Ewings sarcoma.
Nucleic Acids Research | 2017
Joshua P. Plotnik; Peter C. Hollenhorst
Abstract Aberrant activation of RAS/MAPK signaling is a driver of over one third of all human carcinomas. The homologous transcription factors ETS1 and ETS2 mediate activation of gene expression programs downstream of RAS/MAPK signaling. ETS1 is important for oncogenesis in many tumor types. However, ETS2 can act as an oncogene in some cellular backgrounds, and as a tumor suppressor in others, and the molecular mechanism responsible for this cell-type specific function remains unknown. Here, we show that ETS1 and ETS2 can regulate a cell migration gene expression program in opposite directions, and provide the first comparison of the ETS1 and ETS2 cistromes. This genomic data and an ETS1 deletion line reveal that the opposite function of ETS2 is a result of binding site competition and transcriptional attenuation due to weaker transcriptional activation by ETS2 compared to ETS1. This weaker activation was mapped to the ETS2 N-terminus and a specific interaction with the co-repressor ZMYND11 (BS69). Furthermore, ZMYND11 expression levels in patient tumors correlated with oncogenic versus tumor suppressive roles of ETS2. Therefore, these data indicate a novel and specific mechanism allowing ETS2 to switch between oncogenic and tumor suppressive functions in a cell-type specific manner.
Methods of Molecular Biology | 2017
Joshua P. Plotnik; Peter C. Hollenhorst
Identifying gene expression changes mediated by signaling pathways is necessary to determine mechanisms that cause phenotypic change. Recent advances in next-generation sequencing and informatic pipelines have streamlined the ability for laboratories to create and analyze transcriptomic data. Here, we describe the preparation of samples and transcriptomic analysis in order to determine gene expression programs regulated by RAS/ERK signaling.
Cancer Letters | 2018
Sunil Tomar; Joshua P. Plotnik; James Haley; Joshua Scantland; Subramanyam Dasari; Zahir Sheikh; Robert Emerson; Dean Lenz; Peter C. Hollenhorst; Anirban K. Mitra
Metabolic Changes in Ovarian Cancer | 2018
Sunil Tomar; Joshua P. Plotnik; James Haley; Joshua Scantland; Zahir Sheikh; Robert E. Emerson; Dean Lenz; Peter C. Hollenhorst; Anirban K. Mitra
PMC | 2016
Vivekananda Kedage; Nagarathinam Selvaraj; Taylor R. Nicholas; Justin A. Budka; Joshua P. Plotnik; Travis J. Jerde; Peter C. Hollenhorst
PMC | 2014
Joshua P. Plotnik; Justin A. Budka; Mary W. Ferris; Peter C. Hollenhorst